Equities research analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Free Report) in a research report issued on Monday. The brokerage set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright reduced their price objective on shares of Aethlon Medical from $23.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, March 4th.
Check Out Our Latest Research Report on Aethlon Medical
Aethlon Medical Price Performance
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last released its quarterly earnings data on Wednesday, February 14th. The medical equipment provider reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.14). Research analysts anticipate that Aethlon Medical will post -4.98 EPS for the current fiscal year.
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Further Reading
- Five stocks we like better than Aethlon Medical
- What Are Dividend Champions? How to Invest in the Champions
- Garmin Navigates to New Highs Driven By Wearables Trend
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Most active stocks: Dollar volume vs share volume
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.